Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, David Yamauchi, MD, Kofi Poku, PharmD, Van Biglang-awa, PharmD, John E. Shively

Blood (2018) 132 (Supplement 1): 611.

https://doi.org/10.1182/blood-2018-99-116907

Published: 2018

Journal Articles

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Robert Stuver, MD, Niloufer Khan, MD, Marc Schwartz, Mark Acosta, Massimo Federico, MD, Christian Gisselbrecht, Frederick Lansigan, MD, Lauren C. Pinter-Brown, MD, Barbara Pro, MD, Andrei R. Shustov, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Salvia Jain, MD

Blood (2018) 132 (Supplement 1): 2926.

https://doi.org/10.1182/blood-2018-99-112869

Published: 2018

Journal Articles

Is Durability of Response Reported in Refractory CTCL: A Systematic Review

Mehul R Dalal, PhD, Stephen Mitchell, PhD, Conor McCloskey, PhD, Erin Zagadailov, PharmD, MS, Ashish Gautam, PhD

Blood (2017) 130 (Supplement 1): 5598.

https://doi.org/10.1182/blood.V130.Suppl_1.5598.5598

Published: 2017

Journal Articles

NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response

Bartosz Grzywacz, MD, Elizabeth L. Courville, MD, David H. McKenna, MD, Jeffrey S. Miller, MD, Sarah Cooley, MD, Laura Moench, MD

Blood (2017) 130 (Supplement 1): 4459.

https://doi.org/10.1182/blood.V130.Suppl_1.4459.4459

Published: 2017

Journal Articles

Haploidentical Natural Killer Cell Infusion Induces Remission in Non-Hodgkin Lymphoma and Overcomes Resistance to Rituximab

Veronika Bachanova, MD, Dhifaf Sarhan, PhD, Todd E. DeFor, MS, Sarah Cooley, MD, Angela Panoskaltsis-Mortari, PhD, Michael R. Verneris, MD, Bruce R. Blazar, MD, Julie Curtsinger, PhD, Linda J. Burns, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 3030.

https://doi.org/10.1182/blood.V128.22.3030.3030

Published: 2016

Journal Articles

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

Paul A Hamlin, Jr., MD, Michelle A. Fanale, MD, Steven I. Park, MD, David J. Valacer, MD, Jack Higgins, PhD, Anas Younes, MD

Blood (2016) 128 (22): 4200.

https://doi.org/10.1182/blood.V128.22.4200.4200

Published: 2016

Journal Articles

Analysis of Drugs for Hematological Malignancy That Were Granted Accelerated Approval and Feasibility of Randomized Phase 3 Clinical Trials for Relapsed and Refractory Hematological Malignancy

Sumimasa Nagai, MD, PhD, Keiya Ozawa, MD PhD

Blood (2016) 128 (22): 2387.

https://doi.org/10.1182/blood.V128.22.2387.2387

Published: 2016

Journal Articles

Phase I Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Kiyoshi Ando, MD PhD, Ken Ohmachi, MD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Tadashi Nakanishi, Masayuki Namiki, PhD

Blood (2015) 126 (23): 2724.

https://doi.org/10.1182/blood.V126.23.2724.2724

Published: 2015

Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD

Blood (2014) 124 (21): 3097.

https://doi.org/10.1182/blood.V124.21.3097.3097

Published: 2014

Journal Articles

Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience

Juliet Fraser, Antonio Subtil, MD, MBA, Onder Alpdogan, MD, Stuart Seropian, Dennis L. Cooper, MD, Mina Xu, MD, Francine M. Foss, MD

Blood (2013) 122 (21): 5092.

https://doi.org/10.1182/blood.V122.21.5092.5092

Published: 2013

Journal Articles

Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting T reg

Blood (2013) 122 (13): 2185–2194.

https://doi.org/10.1182/blood-2012-09-456988

Published: 2013

Includes: Supplemental data

Journal Articles

Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment

Francine M. Foss, MD, Kenneth R. Carson, MD, Lauren Pinter-Brown, MD, Steven M. Horwitz, MD, Steven T. Rosen, MD, FRCPA, Barbara Pro, MD, Massimo Federico, MD, Christian Gisselbrecht, MD, Eric D. Hsi, MD

Blood (2012) 120 (21): 1614.

https://doi.org/10.1182/blood.V120.21.1614.1614

Published: 2012

Journal Articles

IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,

Sarah Cooley, MD, Veronika Bachanova, Melissa Geller, MD, Michael R Verneris, MD, Bin Zhang, Valarie McCullar, David McKenna, MD, Dixie Lewis, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Philip McGlave, MD, Keli Hippen, Bruce R. Blazar, MD, Jeffrey S. Miller, MD

Blood (2011) 118 (21): 3611.

https://doi.org/10.1182/blood.V118.21.3611.3611

Published: 2011

Journal Articles

Tandem HLA-Mismatched Cadaveric Unrelated Donor Lung Transplant Followed by CD3-and CD19-Depleted Bone Marrow Transplant From the Same Donor Permits Withdrawal of Systemic Immunosuppression with Graft Acceptance and Functional Immune Reconstitution

Paul Szabolcs, Rebecca Buckley, Robert Duane Davis, Judith Voynow, Jerelyn Moffet, Antony Jeyaraj, David W Zaas

Blood (2011) 118 (21): 1006.

https://doi.org/10.1182/blood.V118.21.1006.1006

Published: 2011

Journal Articles

Change In Mast Cell Bone Marrow Burden and In Serum Tryptase Level Are Not Accurate Markers of Response In Patients with Systemic Mastocytosis

Alfonso QuintÁs-Cardama,, MD, Matjaz Sever, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2010) 116 (21): 3073.

https://doi.org/10.1182/blood.V116.21.3073.3073

Published: 2010

Journal Articles

Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma

Stephen M Ansell, MD, PhD, Hui Tang, PhD, Grzegorz S. Nowakowski, MD, Daniel Nikcevich, MD, PhD, Garth D Nelson, Charles Erlichman, MD, Thomas E Witzig, MD, North Central Cancer Treatment Group

Blood (2010) 116 (21): 2862.

https://doi.org/10.1182/blood.V116.21.2862.2862

Published: 2010

Journal Articles

Efficacy of Denileukin Diftitox Retreatment In Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response

Madeleine Duvic, MD, Ann Martin, MD, Elise A. Olsen, MD, David Fivenson, MD, Miles Prince, MD, FRACP, FRCPA

Blood (2010) 116 (21): 2863.

https://doi.org/10.1182/blood.V116.21.2863.2863

Published: 2010

Journal Articles

Effect of Denileukin Diftitox on Pruritus and Other Skin-Related Symptoms Vs Placebo In Patients with Cutaneous T-Cell Lymphoma

Lauren Pinter-Brown, MD, Anna Kozlovski

Blood (2010) 116 (21): 4922.

https://doi.org/10.1182/blood.V116.21.4922.4922

Published: 2010

Journal Articles

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Miles Prince, MD, FRACP, FRCPA, Madeleine Duvic, MD, Ann Martin, MD, Wolfram Sterry, MD, Chalid Assaf, MD, David Straus, MD

Blood (2010) 116 (21): 4158.

https://doi.org/10.1182/blood.V116.21.4158.4158

Published: 2010

NARROW

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Is Durability of Response Reported in Refractory CTCL: A Systematic Review

NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response

Haploidentical Natural Killer Cell Infusion Induces Remission in Non-Hodgkin Lymphoma and Overcomes Resistance to Rituximab

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

Analysis of Drugs for Hematological Malignancy That Were Granted Accelerated Approval and Feasibility of Randomized Phase 3 Clinical Trials for Relapsed and Refractory Hematological Malignancy

Phase I Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience

Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting T reg

Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment

IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,

Tandem HLA-Mismatched Cadaveric Unrelated Donor Lung Transplant Followed by CD3-and CD19-Depleted Bone Marrow Transplant From the Same Donor Permits Withdrawal of Systemic Immunosuppression with Graft Acceptance and Functional Immune Reconstitution

Change In Mast Cell Bone Marrow Burden and In Serum Tryptase Level Are Not Accurate Markers of Response In Patients with Systemic Mastocytosis

Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma

Efficacy of Denileukin Diftitox Retreatment In Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response

Effect of Denileukin Diftitox on Pruritus and Other Skin-Related Symptoms Vs Placebo In Patients with Cutaneous T-Cell Lymphoma

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only